CN109475518B - 梅尼埃病的治疗 - Google Patents

梅尼埃病的治疗

Info

Publication number
CN109475518B
CN109475518B CN201780044883.8A CN201780044883A CN109475518B CN 109475518 B CN109475518 B CN 109475518B CN 201780044883 A CN201780044883 A CN 201780044883A CN 109475518 B CN109475518 B CN 109475518B
Authority
CN
China
Prior art keywords
ebselen
compounds
composition
subject
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780044883.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN109475518A (zh
Inventor
J·奇尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sound Pharmaceuticals Inc
Original Assignee
Sound Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sound Pharmaceuticals Inc filed Critical Sound Pharmaceuticals Inc
Publication of CN109475518A publication Critical patent/CN109475518A/zh
Application granted granted Critical
Publication of CN109475518B publication Critical patent/CN109475518B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201780044883.8A 2016-05-18 2017-05-18 梅尼埃病的治疗 Active CN109475518B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338443P 2016-05-18 2016-05-18
US62/338,443 2016-05-18
PCT/US2017/033379 WO2017201318A1 (en) 2016-05-18 2017-05-18 Treatment of meniere's disease

Publications (2)

Publication Number Publication Date
CN109475518A CN109475518A (zh) 2019-03-15
CN109475518B true CN109475518B (zh) 2026-05-08

Family

ID=60326098

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780044883.8A Active CN109475518B (zh) 2016-05-18 2017-05-18 梅尼埃病的治疗

Country Status (20)

Country Link
US (1) US12427138B2 (enExample)
EP (2) EP3458045B1 (enExample)
JP (1) JP7100866B2 (enExample)
KR (1) KR102474830B1 (enExample)
CN (1) CN109475518B (enExample)
AU (1) AU2017267732B2 (enExample)
CA (1) CA3026007A1 (enExample)
CY (1) CY1127309T1 (enExample)
DK (1) DK3458045T3 (enExample)
ES (1) ES2990157T3 (enExample)
FI (1) FI3458045T3 (enExample)
HR (1) HRP20241559T1 (enExample)
HU (1) HUE069280T2 (enExample)
LT (1) LT3458045T (enExample)
PL (1) PL3458045T3 (enExample)
PT (1) PT3458045T (enExample)
RS (1) RS66167B1 (enExample)
SI (1) SI3458045T1 (enExample)
SM (1) SMT202400469T1 (enExample)
WO (1) WO2017201318A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220145879A (ko) 2020-02-24 2022-10-31 상하이테크 유니버시티 N-치환 피리딜벤즈이소셀라졸론 화합물의 용도
EP4452336A2 (en) * 2021-12-23 2024-10-30 University of Rochester Csf transport pathway for delivery of agents to inner ear
EP4536192A1 (en) 2022-06-06 2025-04-16 Sound Pharmaceuticals Incorporated Amorphous dosage form containing ebselen
EP4536191A1 (en) 2022-06-06 2025-04-16 Sound Pharmaceuticals Incorporated Ebselen containing oral dosage forms
WO2026073143A1 (en) * 2024-09-27 2026-04-02 Sound Pharmaceuticals Inc. Cochlear implant eluting ebselen for treating hearing loss

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140382A2 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments using compounds having erythropoietin activity
WO2016044314A1 (en) * 2014-09-15 2016-03-24 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827093A1 (de) 1988-08-10 1990-02-15 Nattermann A & Cie Verfahren zur herstellung von hochreinem ebselen
DE68921436T2 (de) 1988-12-09 1995-08-10 Allergan Inc Verwendung von 2-substituierten Thiazolidin-4-carbonsäuren zur Behandlung von Katarakt.
CA2472678C (en) 2002-01-04 2013-12-03 Sound Pharmaceuticals Incorporated Otoprotectant compositions of glutathione peroxidase mimics for ameliorating hearing loss
US20070105782A1 (en) 2005-10-07 2007-05-10 Board Of Trustees Of Southern Illinois University Protectant Combinations for Reducing Toxicities
WO2008013866A2 (en) 2006-07-25 2008-01-31 Hough Ear Institute Methods for treating acute acoustic trauma
CA2732686C (en) 2008-12-22 2017-10-03 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
ES2893825T3 (es) * 2011-02-04 2022-02-10 Hough Ear Inst Métodos de tratamiento de lesiones cerebrales
WO2013016727A1 (en) 2011-07-28 2013-01-31 Promentis Pharmaceuticals, Inc. Cysteine prodrugs
CN102526734A (zh) 2012-01-12 2012-07-04 王玉丰 治疗年龄相关性听力损失的药物组合物及其应用
US20150374779A1 (en) 2014-06-26 2015-12-31 Auris Medical Ag Pharmacologic treatments of meniére's disease
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
US10750005B2 (en) 2018-09-27 2020-08-18 International Business Machines Corporation Selective email narration system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140382A2 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments using compounds having erythropoietin activity
WO2016044314A1 (en) * 2014-09-15 2016-03-24 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders

Also Published As

Publication number Publication date
PL3458045T3 (pl) 2025-01-07
CN109475518A (zh) 2019-03-15
JP2019516727A (ja) 2019-06-20
FI3458045T3 (fi) 2024-10-24
HRP20241559T1 (hr) 2025-02-14
EP3458045A4 (en) 2020-09-16
KR20190043499A (ko) 2019-04-26
ES2990157T3 (es) 2024-11-29
US12427138B2 (en) 2025-09-30
EP3458045B1 (en) 2024-08-21
HUE069280T2 (hu) 2025-02-28
KR102474830B1 (ko) 2022-12-06
SMT202400469T1 (it) 2025-01-14
CY1127309T1 (el) 2026-02-25
RS66167B1 (sr) 2024-12-31
LT3458045T (lt) 2024-12-10
US20200261417A1 (en) 2020-08-20
EP3458045A1 (en) 2019-03-27
SI3458045T1 (sl) 2025-03-31
PT3458045T (pt) 2024-10-28
AU2017267732A1 (en) 2018-12-20
CA3026007A1 (en) 2017-11-23
DK3458045T3 (da) 2024-11-04
EP4461360A2 (en) 2024-11-13
EP4461360A3 (en) 2025-01-22
WO2017201318A1 (en) 2017-11-23
JP7100866B2 (ja) 2022-07-14
AU2017267732B2 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
US10835546B2 (en) App specific BACE inhibitors (ASBIs) and uses thereof
EP3458045B1 (en) Ebselen for use in the treatment of meniere's disease
US20100298394A1 (en) Antifungal agents as neuroprotectants
HK1242998A1 (zh) 治疗法布里病的给药方案
JP2023169413A (ja) 精神病性障害を治療するための方法および組成物
US20220202826A1 (en) Methods for treating gi tract disorders
CA3142842A1 (en) Compositions and methods for treating central nervous system disorders
ES2534514T3 (es) Acetato de eslicarbazepina y métodos de uso
WO1998008504A1 (en) Remedies for allergic dermatitis
US20240277641A1 (en) Methods for treating nervous system disorders with antipurinergic agents
HK1205951A1 (en) Use of 7-t-butoxyiminomethylcamptothecin for the prepartion of a medicament for the treatment of uterine neoplasms
WO2025018279A1 (ja) ヒト移植片対宿主病の治療薬およびその組合せ物
EP4719402A1 (en) Sparsentan for use in a method of treating iga-mediated diseases
CN112745279A (zh) 醋甲唑胺及其类似物及其在正常压力脑积水的治疗中的应用
HK1216848B (en) Methods for treating gi tract disorders
HK1104002A (en) Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant